SCHEMBL5852846

SCHEMBL5852846

Cc1ccc(NCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.46
ALDH1A1 P00352 8/20 0.46
KMT2A Q03164 3/20 0.46
NLRP1 Q9C000 1/20 0.46
CA12 O43570 2/20 0.40
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CA9 Q16790 1/20 0.40
AGTR1 P30556 1/20 0.40
GAA P10253 4/20 0.39
CA7 P43166 1/20 0.39
KDM4E B2RXH2 3/20 0.39
POLB P06746 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
MEN1 O00255 2/20 0.38
NPC1 O15118 1/20 0.38
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28373892 1.00 MAPT (0.46) MAPTALDH1A1KMT2ANLRP1CA12
SCHEMBL28373685 0.87 CA12 (0.44) MAPTALDH1A1KMT2ACA12CA1
Fructose SCHEMBL11256679 0.73 TSHR (0.44) MAPTALDH1A1KMT2AGAAPOLB
SCHEMBL444014 0.71 KDM4E (0.48) KDM4ETDP1L3MBTL1LMNA
SCHEMBL10299846 0.71 KDM4E (0.48) KDM4ETDP1L3MBTL1LMNA
SCHEMBL8528869 0.71 KDM4E (0.48) KDM4ETDP1L3MBTL1LMNA
SCHEMBL8829389 0.71 PDE4A (0.43) KDM4ETDP1L3MBTL1LMNA
SCHEMBL22808741 0.70 GAA (0.42) MAPTALDH1A1KMT2AAGTR1GAA
SCHEMBL25262519 0.70 PDE4A (0.42) KDM4ETDP1L3MBTL1LMNA
SCHEMBL19513461 0.70 POLB (0.59) MAPTALDH1A1KMT2ANLRP1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7153971-B2 Contacting a carbohydrate with an amine to produce amino tetrahydroxy carbohydrate, protecting two hydroxy groups of tetrahydroxy carbohydrate, forming hydroxy heterocyclic-spiro moiety by reacting with activated carbonate, oxidizing OH COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2006-12-26 US disclosed
EP-1317460-A4 COMPOUNDS CONTAINING OXAZOLIDINONE MOIETY AND USES THEREOF UNIV COLORADO STATE RES FOUND (US) 2005-04-20 EP disclosed
US-20040039209-A1 Compounds containing oxazolidinone moiety and uses thereof NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2004-02-26 US disclosed
EP-1317460-A1 COMPOUNDS CONTAINING OXAZOLIDINONE MOIETY AND USES THEREOF COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2003-06-11 EP disclosed
WO-2002018391-A1 COMPOUNDS CONTAINING OXAZOLIDINONE MOIETY AND USES THEREOF COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2002-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039209-A1 Compounds containing oxazolidinone moiety and uses thereof OXER1, OXA1L, AOX1 MAPT 4175/4885ALDH1A1 87/4885KMT2A 2658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.